Despite of the common usage of glucocorticoids (GCs), a significant portion of asthma patients exhibit GC insensitivity. This could be mediated by diverse mechanisms, including genomics. Recent work has suggested that measuring changes in gene expression may provide more predictive information about GC insensitivity than baseline gene expression alone, and that expression changes in peripheral blood may be reflective of that in the airway. Through gene expression omnibus (GEO) analysis, we identified IRF1 whose expression is affected by GC treatment in airway smooth muscle (ASM) cells, normal human bronchial epithelial (NHBE) cells, and lymphoblastoid cell lines (LCLs). Significant IRF1 down-regulation post GC exposure was confirmed in two cultured airway epithelial cell lines and primary NHBE cells (p<0.05). We observed large inter-individual variation for GC induced IRF1 expression changes among primary NHBE cells tested. Significant down-regulation of IRF1 was also observed in six randomly selected LCLs (p<0.05) with variable degree of down-regulation among different samples. In peripheral blood mononuclear cells (PBMCs) obtained from healthy volunteers, variable down-regulation of IRF1 by GC was also shown. NFKB1, a gene whose expression is known to be down-regulated by GC and the degree of down-regulation reflective of GC response, was used as a control in our study. IRF1 shows more consistent down-regulation across tissue types when compared to NFKB1. Our results suggest GC induced IRF1 gene expression changes in peripheral blood could be used as a marker to reflect GC response in the airway.